Objective. Intrahepatic cholestasis of pregnancy (ICP) is a common pregnancy-related liver disease and is associated with an increased risk of adverse neonatal outcomes. Ursodeoxycholic acid (UDCA) is the most effective treatment. This study was aimed at investigating the adverse outcomes of ICP and evaluating the effects of treatment with UDCA in patients with ICP. Methods. We included 114 women with ICP and 3725 women without ICP (no-ICP group) who delivered in our hospital between September 2017 and August 2019. The prevalence of ICP in this study was 3.15%. We matched each woman with ICP to five controls. Of all the 114 women with ICP, 73 (64.04%) received UDCA while 41 (35.96%) did not. Logistic multivariate regression analysis was used to compare the adverse outcomes between those with ICP and matched controls as well as between those who received UDCA (UDCA group) and those who did not (non-UDCA group). Results. Compared with controls, women with ICP were more likely to have preeclampsia (adjusted odds ratio, , 95% CI 5.29–52.98), cesarean section (, 95% CI 1.10–2.81), and preterm birth (, 95% CI 2.74–216.67). Administration of UDCA reduced the rate of preterm birth (1.37% vs. 14.63%, , 95% CI 0.01–0.90). Conclusion. ICP increased the risk of preeclampsia, cesarean section, and preterm birth. UDCA could reduce the rate of preterm birth.

中文翻译：

---

妊娠期肝内胆汁淤积及相关母婴不良结局：回顾性病例对照研究

客观。妊娠期肝内胆汁淤积症 (ICP) 是一种常见的妊娠相关肝病，与新生儿不良结局的风险增加有关。熊去氧胆酸（UDCA）是最有效的治疗方法。本研究旨在调查 ICP 的不良后果并评估 UDCA 治疗 ICP 患者的效果。方法. 我们纳入了 2017 年 9 月至 2019 年 8 月在我院分娩的 114 名有 ICP 妇女和 3725 名无 ICP 妇女（无 ICP 组）。本研究中 ICP 的患病率为 3.15%。我们将每位患有 ICP 的女性与五个对照进行匹配。在所有 114 名 ICP 女性中，73 名 (64.04%) 接受了 UDCA，而 41 名 (35.96%) 没有接受。Logistic 多元回归分析用于比较 ICP 患者与匹配对照之间以及接受 UDCA 的患者（UDCA 组）和未接受 UDCA 的患者（非 UDCA 组）之间的不良结果。结果。与对照组相比，患有 ICP 的女性更容易发生先兆子痫（调整优势比，, 95% CI 5.29–52.98), 剖宫产 (, 95% CI 1.10–2.81) 和早产 (, 95% CI 2.74–216.67)。UDCA 的使用降低了早产率（1.37% vs. 14.63%，, 95% CI 0.01–0.90)。结论。ICP增加了先兆子痫、剖宫产和早产的风险。UDCA 可以降低早产率。